Pfizer Inc.

NYSE:PFE  
43.16
+0.30 (+0.70%)
5:18:50 PM EDT: $43.10 -0.06 (-0.14%)
Products, Strategic Combinations, Regulatory

Pfizer, Valneva Launch Phase 2 Study For Lyme Disease Vaccine Candidate

Published: 03/08/2021 06:13 GMT
Pfizer Inc. (PFE) - Reg-valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate.
Phase 2 Study Will Include Both Adult and Pediatric Subjects With an Aim to Support Acceleration of Vaccine Candidate's Pediatric Program.
Vla15 Will Be Tested at Two Different Schedules (month 0-2-6 Or Month 0-6) Receiving Selected Dose of 180Μg.
Vla15 is Only Lyme Disease Vaccine Candidate in Active Clinical Development.
Vla15-221 Study Builds on Previous Positive Phase 2 Studies, Incorporates New Dose Regimens and is Anticipated to Be Final Phase 2 Study Readout Before a Decision to Progress Into Pivotal Phase 3 Studies.
First Dose in This Study Will Trigger a Milestone Payment of $10 Million From Pfizer to Valneva.
Are Pleased That, Together With Our Partner Pfizer, We Have Decided to Pursue This Development on Lyme Product While Preparing for a Potential Phase 3 Start.